A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Etrumadenant (Primary) ; Zimberelimab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Pharyngeal neoplasms; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms PANTHEoN
- 27 Oct 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Sep 2023 Planned End Date changed from 1 Aug 2025 to 1 Dec 2026.
- 25 Sep 2023 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.